Original articleHuman Papillomavirus Vaccination: What Are the Reasons for Nonvaccination Among U.S. Adolescents?
Section snippets
Sample
The National Immunization Survey-Teen (NIS-Teen) is the primary U.S. surveillance database for adolescent vaccination. Specifically, it is an add-on survey to the National Immunization Survey, which targets noninstitutionalized households with 19- to 35-month-old children. The National Immunization Survey uses a dual-sampling frame with random digit dialing. Those households contacted by this survey were then screened for the presence of one randomly selected 13- to 17-year-old adolescent for
Results
Approximately, a quarter of the sample is represented by each survey year, respectively. The sample reported on 58.8% male and 41.2% female adolescents aged 13–17 years. Among the respondents in the sample, 31.6% were not too likely to receive the HPV vaccine, 51.9% were not likely at all to receive the HPV vaccine, and 16.5% were not sure or did not know. Respondents in this sample included 68.0% mothers or female guardian, 25.6% fathers or male guardian, 3.0% grandparents, and the remaining
Discussion
The suboptimal HPV vaccination rates in the United States warrant an investigation of reasons for vaccine hesitancy over time. Moreover, differences by sex of the child and level of vaccine hesitancy were assessed to see how these were associated with primary reasons for nonvaccination.
First, reasons for nonvaccination differed over time. Specifically, the HPV vaccine being not recommended, the adolescent reported as not sexually active and having a lack of knowledge were more likely to be
Acknowledgments
A portion of this publication was presented as an abstract at the International Papillomavirus Conference, 2017. The authors would like to acknowledge the data source, which made this analysis possible. U.S. Department of Health and Human Services (DHHS), National Center for Health Statistics. The 2012–2015 National Immunization Survey-Teen, Hyattsville, Maryland: Centers for Disease Control and Prevention, 2013–2016.
References (47)
- et al.
Acceptability of the human papillomavirus vaccine and reasons for non-vaccination among parents of adolescent sons
Vaccine
(2014) - et al.
HPV vaccine hesitancy: Findings from a statewide survey of health care providers
J Pediatr Health Care
(2014) - et al.
Age at HPV vaccine initiation and completion among US adolescent girls: Trend from 2008 to 2012
Vaccine
(2015) - et al.
Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012
Vaccine
(2014) - et al.
A systematic review of interventions for reducing parental vaccine refusal and vaccine hesitancy
Vaccine
(2013) - et al.
Relationship status impacts primary reasons for interest in the HPV vaccine among young adult women
Vaccine
(2016) - et al.
Educational interventions to increase HPV vaccination acceptance: A systematic review
Vaccine
(2014) - et al.
Physician communication about adolescent vaccination: How is human papillomavirus vaccine different?
Prev Med
(2015) - et al.
Factors associated with human papillomavirus vaccine-series initiation and healthcare provider recommendation in US adolescent females: 2007 National Survey of Children's Health
Vaccine
(2012) - et al.
Characteristics of adolescents lacking provider-recommended human papillomavirus vaccination
J Adolesc Health
(2017)
Missed clinical opportunities: Provider recommendations for HPV vaccination for 11-12 year old girls are limited
Vaccine
Do the media provide transparent health information? A cross-cultural comparison of public information about the HPV vaccine
Vaccine
Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008
Sex Transm Dis
Human papillomavirus-associated cancers - United States, 2008-2012
MMWR Morb Mortal Wkly Rep
Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices
MMWR Morb Mortal Wkly Rep
Immunization and infectious Diseases
National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2015
MMWR Morb Mortality Weekly Rep
Provider recommendation mediates the relationship between parental human papillomavirus (HPV) vaccine awareness and HPV vaccine initiation and completion among 13- to 17-year-old U.S. adolescent children
Clin Pediatr
HPV vaccine decision making in pediatric primary care: A semi-structured interview study
BMC Pediatr
Integrating clinical, community, and policy perspectives on HPV vaccination
Annu Rev Public Health
Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: A systematic review from 2001 to 2011
Obstet Gynecol Int
Quadrivalent human papillomavirus vaccine: Recommendations of the advisory committee on immunization practices (ACIP)
MMWR Recomm Rep
Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011
MMWR Morb Mortal Wkly Rep
Cited by (56)
Human Papillomavirus Vaccine Hesitancy in the United States
2023, Pediatric Clinics of North AmericaCentralized Reminder/Recall for Human Papillomavirus Vaccination: Findings From Two States—A Randomized Clinical Trial
2021, Journal of Adolescent HealthCitation Excerpt :While there is some disagreement around the definition of “hesitancy” in the literature [38–40], reminding parents may not be effective if parents have significant underlying concerns about the vaccine. Studies have shown that the reasons for HPV vaccine hesitancy include lack of a provider recommendation, misinformation about the vaccine, and concerns over vaccine safety or efficacy [41–44]. A recent survey in a nationally representative sample of US parents demonstrated an overall hesitancy rate of about 23% for HPV, with safety being a major source of concern.
Conflicts of interest: E.M.D. has served on the U.S. HPV Vaccine Advisory Board for Merck Pharmaceuticals. The other authors have no conflicts of interest to disclose.
Clinical Trial Registry: Not applicable.